Mankind Pharma
New to Zerodha? Sign-up for free.
New to Zerodha? Sign-up for free.
Get instant stock alerts
- Share Price
- Financials
- Revenue mix
- Shareholdings
- Peers
- Forensics
Share Price
Coming soon
- 5D
- 1M
- 6M
- YTD
- 1Y
- 5Y
- MAX
Financials
-
Summary
-
Profit & Loss
-
Balance sheet
-
Cashflow
This data is currently unavailable for this company.
| (In Cr.) |
|---|
| (In Cr.) | ||||
|---|---|---|---|---|
|
This data is currently unavailable for this company. |
| (In %) |
|---|
| (In Cr.) |
|---|
| Financial Year (In Cr.) |
|---|
Revenue mix
-
Product wise
-
Location wise
Revenue Mix
This data is currently unavailable for this company.
Revenue Mix
This data is currently unavailable for this company.
Forensics
Recent events
-
News
-
Corporate Actions
June 2 (Reuters) - Mankind Pharma Ltd MNKI.NS:
UNIT BUYS REMAINING 10% STAKE IN UPAKARMA
ACQUISITION COST FOR 10% STAKE IN UPAKARMA IS 7.5 MILLION RUPEES
Source text: ID:nBSE97jdLy
Further company coverage: MNKI.NS
(([email protected];))
June 2 (Reuters) - Mankind Pharma Ltd MNKI.NS:
UNIT BUYS REMAINING 10% STAKE IN UPAKARMA
ACQUISITION COST FOR 10% STAKE IN UPAKARMA IS 7.5 MILLION RUPEES
Source text: ID:nBSE97jdLy
Further company coverage: MNKI.NS
(([email protected];))
By Pranav Kashyap
BENGALURU, May 21 (Reuters) - India's Mankind Pharma MNKI.NS may raise condom prices if the Middle East conflict drags on further and keeps oil prices elevated, its chief executive told Reuters on Thursday.
The company, which makes Manforce condoms and is the market leader with a share of about 30%, has enough stock to last for a few months if the war persists, CEO Sheetal Arora said, but warned that Mankind may have to pass some of the higher costs to customers if oil prices remain elevated.
He did not specify a timeline for a potential price increase.
Tensions in the Middle East have rattled global markets, with supply disruptions lifting oil prices LCOc1 by about 50% to above $100 a barrel since the war began in late February.
Oil is a key cost for condom makers as they rely on petroleum-linked raw materials such as chemicals, lubricants and packaging, although the base is natural latex.
Malaysia's Karex KARE.KL, the world's largest condom maker, also plans to raise prices by 20% to 30% as the war drives up the cost of raw materials and shipping.
Mankind's fourth-quarter results showed raw material costs were broadly flat, rising less than 0.5% both quarter-on-quarter and from a year earlier.
Manforce condoms typically sell for about 100 rupees ($1.04) to 150 rupees ($1.56) for a 10-pack - among the cheapest in India.
INDIA'S WEIGHT-LOSS DRUG MARKET GAINS MOMENTUM
Separately, Arora said Mankind was betting on its generic semaglutide weight-loss injection and was looking to expand into tier-2 and tier-3 cities.
The company launched the injection in the first week of April amid intensifying competition in India's fast-growing weight-loss drug market, where therapies range from low-cost generic semaglutide at about 1,300 rupees to premium options, such as tirzepatide, priced up to 27,000 rupees.
"Right now it's a mad rush ... very crowded market," Arora said, adding it was too early to quantify the demand for Mankind's product.
($1 = 96.2000 Indian rupees)
(Reporting by Pranav Kashyap in Bengaluru; Editing by Chandini Monnappa and Sonia Cheema)
(([email protected]; +919886482111;))
By Pranav Kashyap
BENGALURU, May 21 (Reuters) - India's Mankind Pharma MNKI.NS may raise condom prices if the Middle East conflict drags on further and keeps oil prices elevated, its chief executive told Reuters on Thursday.
The company, which makes Manforce condoms and is the market leader with a share of about 30%, has enough stock to last for a few months if the war persists, CEO Sheetal Arora said, but warned that Mankind may have to pass some of the higher costs to customers if oil prices remain elevated.
He did not specify a timeline for a potential price increase.
Tensions in the Middle East have rattled global markets, with supply disruptions lifting oil prices LCOc1 by about 50% to above $100 a barrel since the war began in late February.
Oil is a key cost for condom makers as they rely on petroleum-linked raw materials such as chemicals, lubricants and packaging, although the base is natural latex.
Malaysia's Karex KARE.KL, the world's largest condom maker, also plans to raise prices by 20% to 30% as the war drives up the cost of raw materials and shipping.
Mankind's fourth-quarter results showed raw material costs were broadly flat, rising less than 0.5% both quarter-on-quarter and from a year earlier.
Manforce condoms typically sell for about 100 rupees ($1.04) to 150 rupees ($1.56) for a 10-pack - among the cheapest in India.
INDIA'S WEIGHT-LOSS DRUG MARKET GAINS MOMENTUM
Separately, Arora said Mankind was betting on its generic semaglutide weight-loss injection and was looking to expand into tier-2 and tier-3 cities.
The company launched the injection in the first week of April amid intensifying competition in India's fast-growing weight-loss drug market, where therapies range from low-cost generic semaglutide at about 1,300 rupees to premium options, such as tirzepatide, priced up to 27,000 rupees.
"Right now it's a mad rush ... very crowded market," Arora said, adding it was too early to quantify the demand for Mankind's product.
($1 = 96.2000 Indian rupees)
(Reporting by Pranav Kashyap in Bengaluru; Editing by Chandini Monnappa and Sonia Cheema)
(([email protected]; +919886482111;))
** Shares of Mankind Pharma MNKI.NS rise 2.9% to 2,565 rupees
** Drugmaker reports 30.4% Y/Y profit growth in Q4 led by strong demand for its chronic therapies
** Rev from ops up 12% Y/Y
** Motilal Oswal says MNKI's profit and EBITDA beat its expectations on strength in its domestic business
** Avg rating of 17 analysts on MNKI at "buy"; median PT is 2,500 rupees - data compiled by LSEG
** YTD, stock up 16.8%
(Reporting by Kashish Tandon in Bengaluru)
** Shares of Mankind Pharma MNKI.NS rise 2.9% to 2,565 rupees
** Drugmaker reports 30.4% Y/Y profit growth in Q4 led by strong demand for its chronic therapies
** Rev from ops up 12% Y/Y
** Motilal Oswal says MNKI's profit and EBITDA beat its expectations on strength in its domestic business
** Avg rating of 17 analysts on MNKI at "buy"; median PT is 2,500 rupees - data compiled by LSEG
** YTD, stock up 16.8%
(Reporting by Kashish Tandon in Bengaluru)
May 19 (Reuters) - Mankind Pharma Ltd MNKI.NS:
MANKIND PHARMA MARCH-QUARTER CONSOL PROFIT FROM CONTINUING OPERATIONS 5.59 BILLION RUPEES
MANKIND PHARMA MARCH-QUARTER CONSOL REVENUE FROM OPERATIONS 34.43 BILLION RUPEES
MANKIND PHARMA - APPROVED ADDITIONAL INVESTMENT OF UP TO 5 BILLION RUPEES IN MANKIND MEDICARE , IN ONE OR MORE TRANCHES
Further company coverage: MNKI.NS
(([email protected];))
May 19 (Reuters) - Mankind Pharma Ltd MNKI.NS:
MANKIND PHARMA MARCH-QUARTER CONSOL PROFIT FROM CONTINUING OPERATIONS 5.59 BILLION RUPEES
MANKIND PHARMA MARCH-QUARTER CONSOL REVENUE FROM OPERATIONS 34.43 BILLION RUPEES
MANKIND PHARMA - APPROVED ADDITIONAL INVESTMENT OF UP TO 5 BILLION RUPEES IN MANKIND MEDICARE , IN ONE OR MORE TRANCHES
Further company coverage: MNKI.NS
(([email protected];))
- Theravance Biopharma settled Hatch-Waxman patent litigation over YUPELRI (revefenacin) inhalation solution with Mankind Pharma, clearing a path for a future generic launch.
- Settlement grants Mankind a royalty-free, non-exclusive US license to launch its generic on or after April 23, 2039.
- Agreement resolves claims tied to Mankind ANDA filing that sought approval to sell a generic before expiry of patents asserted by Theravance, with Viatris unit Mylan as exclusive US sublicencee.
- All pending Hatch-Waxman litigation related to YUPELRI has been resolved.
- Deal remains subject to US Department of Justice, Federal Trade Commission review.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Theravance Biopharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-26-036870), on March 30, 2026, and is solely responsible for the information contained therein.
- Theravance Biopharma settled Hatch-Waxman patent litigation over YUPELRI (revefenacin) inhalation solution with Mankind Pharma, clearing a path for a future generic launch.
- Settlement grants Mankind a royalty-free, non-exclusive US license to launch its generic on or after April 23, 2039.
- Agreement resolves claims tied to Mankind ANDA filing that sought approval to sell a generic before expiry of patents asserted by Theravance, with Viatris unit Mylan as exclusive US sublicencee.
- All pending Hatch-Waxman litigation related to YUPELRI has been resolved.
- Deal remains subject to US Department of Justice, Federal Trade Commission review.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Theravance Biopharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-26-036870), on March 30, 2026, and is solely responsible for the information contained therein.
**Morgan Stanley initiates Torrent Pharma TORP.NS with "Equal-weight" and PT of 4,580 rupees; and Mankind Pharma MNKI.NS with "Overweight" and PT of 2,500 rupees
**Brokerage says both the Indian pharma companies are long-term compounding franchises supported by chronic therapies, pricing, and new launches
**However, brokerage prefers MNKI on earnings recovery potential and scaling of BSV unit, plus supportive valuations
**Says TORP's growth and synergy potential already reflected in current valuations after recent re-rating
**Expects MNKI to have revenue growth at a CAGR of 11% from FY26 to FY28
**Sees TORP and JB Chemicals merger to have cost synergies of 3 billion rupees ($31.82 million) and 4.5 billion rupees in FY28 and FY29, respectively
**Shares of Torrent Pharma TORP.NS down 0.8% at 4,265 rupees, while Mankind Pharma MNKI.NS flat at 2,024 rupees
**YTD, TORP up 11.2%; MNKI down 7.6%
($1 = 94.2730 Indian rupees)
(Reporting by Mridula Kumar in Bengaluru)
(([email protected];))
**Morgan Stanley initiates Torrent Pharma TORP.NS with "Equal-weight" and PT of 4,580 rupees; and Mankind Pharma MNKI.NS with "Overweight" and PT of 2,500 rupees
**Brokerage says both the Indian pharma companies are long-term compounding franchises supported by chronic therapies, pricing, and new launches
**However, brokerage prefers MNKI on earnings recovery potential and scaling of BSV unit, plus supportive valuations
**Says TORP's growth and synergy potential already reflected in current valuations after recent re-rating
**Expects MNKI to have revenue growth at a CAGR of 11% from FY26 to FY28
**Sees TORP and JB Chemicals merger to have cost synergies of 3 billion rupees ($31.82 million) and 4.5 billion rupees in FY28 and FY29, respectively
**Shares of Torrent Pharma TORP.NS down 0.8% at 4,265 rupees, while Mankind Pharma MNKI.NS flat at 2,024 rupees
**YTD, TORP up 11.2%; MNKI down 7.6%
($1 = 94.2730 Indian rupees)
(Reporting by Mridula Kumar in Bengaluru)
(([email protected];))
Novo Nordisk's India patent on semaglutide expires this week
Move to trigger wave of cheaper generics from local drugmakers
Concerns raised about misuse, uneven oversight
By Rishika Sadam
HYDERABAD, March 19 (Reuters) - India's market for diabetes and weight-loss drugs is set for a shake-up as Danish drugmaker Novo Nordisk's NOVOb.CO patent on semaglutide expires this week, triggering a wave of cheaper generics from local drugmakers and worries about uneven oversight in an overcrowded market.
More than 40 Indian firms are expected to launch over 50 brands within weeks, analysts and doctors said, widening access in a price-sensitive market, but also raising concerns about misuse and confusion among prescribers as costs fall sharply.
Sun Pharma SUN.NS, Mankind Pharma MNKI.NS, Dr. Reddy's REDY.NS, Zydus ZYDU.NS, Lupin LUPN.NS and Alkem ALKE.NS are among the companies expected to launch generic versions of semaglutide, the active ingredient in Novo's diabetes drug Ozempic and weight-loss treatment Wegovy.
"With high demand, falling prices and multiple brands, you may see direct pharmacy purchases, distributor-level leakages, or cosmetic or lifestyle use especially in urban markets," said Salil Kallianpur, an independent analyst.
"This could lead to misuse, poor titration and unmanaged side effects and eventually regulatory tightening."
India's drug regulator did not respond to a request for comment. Semaglutide is a prescription drug, but enforcement in India has often been uneven, with doctors and pharmacists playing a key gatekeeping role.
The entry of generics will also challenge Novo and U.S. rival Eli Lilly LLY.N, which launched blockbuster diabetes and obesity drugs in India last year, as they seek to cement their position in the country.
Lilly's Mounjaro became India's top-selling drug by value within months of launch, according to data from Pharmarack, a research firm.
India, the world's most populous nation, has the second-highest number of adults with diabetes after China and could have more than 440 million overweight or obese people by 2050, according to The Lancet, a medical journal, and the International Diabetes Federation.
India's obesity drug market could grow to 80 billion rupees ($856.6 million) by 2030 from about 15 billion rupees today, according to Pharmarack estimates.
EYES ON THE PRICE
Indian generic drugmakers, known globally for producing low-cost medicines, are expected to price their generics at discounts of at least 50% to 60%.
Analysts say monthly prices for the lowest dose could fall from about 11,000 rupees to 3,000 to 5,000 rupees as early generics arrive and eventually to around 1,500 to 2,500 rupees, expanding access beyond a niche urban elite.
"I will consult my doctor to check if I can move to using a generic version, as that appears to be lighter on the pocket," said 32-year-old Vishal, a tech worker from Hyderabad, who is considering a switch from Wegovy.
Many other patients in India's out-of-pocket market have also begun enquiring about cheaper options, some of which are expected to launch as soon as Saturday, the day after Novo's patent expires.
"The price range being quoted is broadly 2,500 to 3,500 rupees, which is quite low," said bariatric surgeon Venugopal Pareek. Six of his patients are waiting for generic versions to switch from Novo or Lilly drugs.
Lower prices are expected to expand the patient pool.
"Onboarding of patients from lower economic strata may happen on branded generics," said Sheetal Sapale, commercial vice president at Pharmarack, noting that company profits would depend on pricing discipline.
Novo and Lilly did not immediately respond to Reuters requests for a comment.
DOCTORS' CHOICE
Even as prices fall, analysts say the winner in the market will depend not just on cost, but also on doctor confidence.
India's pharmaceutical market is heavily driven by physician prescriptions and uptake will depend on doctors' familiarity and confidence in individual brands.
An initial glut of products is likely to overwhelm prescribers, analysts said, with uneven experiences and aggressive marketing.
Many generic drugmakers are opting for brand names that incorporate "sema," which could also add to confusion.
Over time, analysts expect doctors' trust to consolidate around a handful of players offering reliable supply, quality delivery devices and consistent outcomes.
"Weaker players with poor quality and no differentiation will likely exit within two to three years," Kallianpur said.
(Reporting by Rishika Sadam; Editing by Dhanya Skariachan and Thomas Derpinghaus)
(([email protected];))
Novo Nordisk's India patent on semaglutide expires this week
Move to trigger wave of cheaper generics from local drugmakers
Concerns raised about misuse, uneven oversight
By Rishika Sadam
HYDERABAD, March 19 (Reuters) - India's market for diabetes and weight-loss drugs is set for a shake-up as Danish drugmaker Novo Nordisk's NOVOb.CO patent on semaglutide expires this week, triggering a wave of cheaper generics from local drugmakers and worries about uneven oversight in an overcrowded market.
More than 40 Indian firms are expected to launch over 50 brands within weeks, analysts and doctors said, widening access in a price-sensitive market, but also raising concerns about misuse and confusion among prescribers as costs fall sharply.
Sun Pharma SUN.NS, Mankind Pharma MNKI.NS, Dr. Reddy's REDY.NS, Zydus ZYDU.NS, Lupin LUPN.NS and Alkem ALKE.NS are among the companies expected to launch generic versions of semaglutide, the active ingredient in Novo's diabetes drug Ozempic and weight-loss treatment Wegovy.
"With high demand, falling prices and multiple brands, you may see direct pharmacy purchases, distributor-level leakages, or cosmetic or lifestyle use especially in urban markets," said Salil Kallianpur, an independent analyst.
"This could lead to misuse, poor titration and unmanaged side effects and eventually regulatory tightening."
India's drug regulator did not respond to a request for comment. Semaglutide is a prescription drug, but enforcement in India has often been uneven, with doctors and pharmacists playing a key gatekeeping role.
The entry of generics will also challenge Novo and U.S. rival Eli Lilly LLY.N, which launched blockbuster diabetes and obesity drugs in India last year, as they seek to cement their position in the country.
Lilly's Mounjaro became India's top-selling drug by value within months of launch, according to data from Pharmarack, a research firm.
India, the world's most populous nation, has the second-highest number of adults with diabetes after China and could have more than 440 million overweight or obese people by 2050, according to The Lancet, a medical journal, and the International Diabetes Federation.
India's obesity drug market could grow to 80 billion rupees ($856.6 million) by 2030 from about 15 billion rupees today, according to Pharmarack estimates.
EYES ON THE PRICE
Indian generic drugmakers, known globally for producing low-cost medicines, are expected to price their generics at discounts of at least 50% to 60%.
Analysts say monthly prices for the lowest dose could fall from about 11,000 rupees to 3,000 to 5,000 rupees as early generics arrive and eventually to around 1,500 to 2,500 rupees, expanding access beyond a niche urban elite.
"I will consult my doctor to check if I can move to using a generic version, as that appears to be lighter on the pocket," said 32-year-old Vishal, a tech worker from Hyderabad, who is considering a switch from Wegovy.
Many other patients in India's out-of-pocket market have also begun enquiring about cheaper options, some of which are expected to launch as soon as Saturday, the day after Novo's patent expires.
"The price range being quoted is broadly 2,500 to 3,500 rupees, which is quite low," said bariatric surgeon Venugopal Pareek. Six of his patients are waiting for generic versions to switch from Novo or Lilly drugs.
Lower prices are expected to expand the patient pool.
"Onboarding of patients from lower economic strata may happen on branded generics," said Sheetal Sapale, commercial vice president at Pharmarack, noting that company profits would depend on pricing discipline.
Novo and Lilly did not immediately respond to Reuters requests for a comment.
DOCTORS' CHOICE
Even as prices fall, analysts say the winner in the market will depend not just on cost, but also on doctor confidence.
India's pharmaceutical market is heavily driven by physician prescriptions and uptake will depend on doctors' familiarity and confidence in individual brands.
An initial glut of products is likely to overwhelm prescribers, analysts said, with uneven experiences and aggressive marketing.
Many generic drugmakers are opting for brand names that incorporate "sema," which could also add to confusion.
Over time, analysts expect doctors' trust to consolidate around a handful of players offering reliable supply, quality delivery devices and consistent outcomes.
"Weaker players with poor quality and no differentiation will likely exit within two to three years," Kallianpur said.
(Reporting by Rishika Sadam; Editing by Dhanya Skariachan and Thomas Derpinghaus)
(([email protected];))
March 18 (Reuters) - Mankind Pharma Ltd MNKI.NS:
MANKIND PHARMA - BUYS RIVOTRIL BRAND FROM ROCHE FOR INDIA
MANKIND PHARMA - BUYS EXCLUSIVE RIGHTS TO MANUFACTURE, MARKET AND DISTRIBUTE RIVOTRIL IN INDIA
Source text: ID:nNSE4BvRfv
Further company coverage: MNKI.NS
(([email protected];;))
March 18 (Reuters) - Mankind Pharma Ltd MNKI.NS:
MANKIND PHARMA - BUYS RIVOTRIL BRAND FROM ROCHE FOR INDIA
MANKIND PHARMA - BUYS EXCLUSIVE RIGHTS TO MANUFACTURE, MARKET AND DISTRIBUTE RIVOTRIL IN INDIA
Source text: ID:nNSE4BvRfv
Further company coverage: MNKI.NS
(([email protected];;))
Feb 26 (Reuters) - Mankind Pharma Ltd MNKI.NS:
MANKIND PHARMA - TAX PENALTY OF 10.2 MILLION RUPEES DROPPED
Source text: ID:nBSE5Lhcbn
Further company coverage: MNKI.NS
(([email protected];))
Feb 26 (Reuters) - Mankind Pharma Ltd MNKI.NS:
MANKIND PHARMA - TAX PENALTY OF 10.2 MILLION RUPEES DROPPED
Source text: ID:nBSE5Lhcbn
Further company coverage: MNKI.NS
(([email protected];))
Feb 16 (Reuters) - Mankind Pharma Ltd MNKI.NS:
MANKIND PHARMA - TAX PENALTY OF 4.6 MILLION RUPEES DROPPED
Source text: ID:nBSE6Fryr5
Further company coverage: MNKI.NS
(([email protected];;))
Feb 16 (Reuters) - Mankind Pharma Ltd MNKI.NS:
MANKIND PHARMA - TAX PENALTY OF 4.6 MILLION RUPEES DROPPED
Source text: ID:nBSE6Fryr5
Further company coverage: MNKI.NS
(([email protected];;))
Feb 9 (Reuters) - Mankind Pharma Ltd MNKI.NS:
MANKIND PHARMA - SEARCH AND SEIZURE/INSPECTION OPERATION CONDUCTED BY GST DEPARTMENT AT BHARAT SERUMS AND VACCINES
MANKIND PHARMA - UNIT OPERATIONS CONTINUED AS USUAL DURING INSPECTION
MANKIND PHARMA - OPERATION CONDUCTED FROM FEBRUARY 03 TO FEBRUARY 08, 2026
MANKIND PHARMA - BUSINESS OPERATIONS OF BSV CONTINUED AS USUAL DURING SEARCH
Source text: ID:nBSE5vjTMb
Further company coverage: MNKI.NS
(([email protected];))
Feb 9 (Reuters) - Mankind Pharma Ltd MNKI.NS:
MANKIND PHARMA - SEARCH AND SEIZURE/INSPECTION OPERATION CONDUCTED BY GST DEPARTMENT AT BHARAT SERUMS AND VACCINES
MANKIND PHARMA - UNIT OPERATIONS CONTINUED AS USUAL DURING INSPECTION
MANKIND PHARMA - OPERATION CONDUCTED FROM FEBRUARY 03 TO FEBRUARY 08, 2026
MANKIND PHARMA - BUSINESS OPERATIONS OF BSV CONTINUED AS USUAL DURING SEARCH
Source text: ID:nBSE5vjTMb
Further company coverage: MNKI.NS
(([email protected];))
Feb 3 (Reuters) - Mankind Pharma Ltd MNKI.NS:
MANKIND PHARMA Q3 CONSOL NET PROFIT 4.09 BILLION RUPEES
MANKIND PHARMA Q3 CONSOL REVENUE FROM OPERATIONS 35.67 BILLION RUPEES
Source text: [ID:]
Further company coverage: MNKI.NS
(([email protected];;))
Feb 3 (Reuters) - Mankind Pharma Ltd MNKI.NS:
MANKIND PHARMA Q3 CONSOL NET PROFIT 4.09 BILLION RUPEES
MANKIND PHARMA Q3 CONSOL REVENUE FROM OPERATIONS 35.67 BILLION RUPEES
Source text: [ID:]
Further company coverage: MNKI.NS
(([email protected];;))
Aug 19 (Reuters) - Mankind Pharma Ltd MNKI.NS:
WHOLLY OWNED SUBSIDIARY HAS BEEN INCORPORATED IN RUSSIA
Source text: [ID:]
Further company coverage: MNKI.NS
(([email protected];;))
Aug 19 (Reuters) - Mankind Pharma Ltd MNKI.NS:
WHOLLY OWNED SUBSIDIARY HAS BEEN INCORPORATED IN RUSSIA
Source text: [ID:]
Further company coverage: MNKI.NS
(([email protected];;))
July 24 (Reuters) - Mankind Pharma Ltd MNKI.NS:
INCORPORATES WHOLLY OWNED SUBSIDIARY IN SRI LANKA
Source text: ID:nBSEqYRCl
Further company coverage: MNKI.NS
(([email protected];;))
July 24 (Reuters) - Mankind Pharma Ltd MNKI.NS:
INCORPORATES WHOLLY OWNED SUBSIDIARY IN SRI LANKA
Source text: ID:nBSEqYRCl
Further company coverage: MNKI.NS
(([email protected];;))
** Shares of Mankind Pharma MNKI.NS rise 4.75% to 2664.4 rupees
** Jefferies reiterates "buy" and hikes price target to 3,000 rupees from 2,870 rupees, implying an upside of 19%
** Jefferies' new price target is the third highest among the 16 analysts covering the stock
** Brokerage sees earnings and growth recovery ahead as Mankind emerges from nine challenging months of core business reorganization and Bharat Serums & Vaccines (BSV) integration
** Expects growth to normalize in the second half of the fiscal 2026 and says valuations remain attractive
** Forecasts fiscal 2027 to be even stronger than FY2026 and estimates 1.5x growth in Indian pharmaceutical market (IPM)
** The average rating of 16 analysts tracking MNKI is "buy"; median PT is 2,730 rupees, according to data compiled by LSEG
** MNKI shares are down 11.7% in 2025 so far, underperforming the 4.7% drop in pharma index .NIPHARM, exchange data shows
(Reporting by Bharath Rajeswaran in Bengaluru)
(([email protected]; +91 9769003463;))
** Shares of Mankind Pharma MNKI.NS rise 4.75% to 2664.4 rupees
** Jefferies reiterates "buy" and hikes price target to 3,000 rupees from 2,870 rupees, implying an upside of 19%
** Jefferies' new price target is the third highest among the 16 analysts covering the stock
** Brokerage sees earnings and growth recovery ahead as Mankind emerges from nine challenging months of core business reorganization and Bharat Serums & Vaccines (BSV) integration
** Expects growth to normalize in the second half of the fiscal 2026 and says valuations remain attractive
** Forecasts fiscal 2027 to be even stronger than FY2026 and estimates 1.5x growth in Indian pharmaceutical market (IPM)
** The average rating of 16 analysts tracking MNKI is "buy"; median PT is 2,730 rupees, according to data compiled by LSEG
** MNKI shares are down 11.7% in 2025 so far, underperforming the 4.7% drop in pharma index .NIPHARM, exchange data shows
(Reporting by Bharath Rajeswaran in Bengaluru)
(([email protected]; +91 9769003463;))
Updates paragraph 1, adds details on Novo Nordisk and Eli Lilly
June 26 (Reuters) - India's drug regulator on Thursday approved the launch of pre-filled injector pens of Eli Lilly's LLY.N blockbuster weight-loss drug, Mounjaro, giving the company more options to compete with rival Novo Nordisk's NOVOb.CO recently launched Wegovy.
India, the world's most populous country, has high obesity rates and the second-highest number of people with type 2 diabetes. Around 11% of Indian adults are expected to become obese by 2035, according to the World Obesity Federation Atlas.
Here are the local and international drugmakers also eyeing the Indian market and looking to introduce rivals to Lilly's drug:
NOVO NORDISK
The Danish drugmaker launched its blockbuster weight-loss drug Wegovy in India on June 24, three months after Eli Lilly began marketing its rival product Mounjaro.
The active ingredient in Wegovy is semaglutide, which is likely to go off-patent in 2026 in India.
Wegovy and Lilly's Mounjaro belong to the same class of treatments called GLP-1 agonists, which soared into popularity globally triggering a shortage of supply.
GLP-1 drugs mimic a gut hormone that helps control blood sugar levels and slow digestion, making people feel fuller for longer.
ELI LILLY
Lilly started selling Mounjaro in India in late March for diabetes and obesity, beating rival Novo to the market. The doses available were 2.5 mg and 5 mg vials.
On Thursday, Mounjaro KwikPen - for once-weekly use - was approved by the Central Drugs Standard Control Organization for six dose strengths of 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg and 15 mg.
SUN PHARMA
Sun Pharmaceutical SUN.NS, India's largest drugmaker by revenue, is developing its own GLP-1 treatment, utreglutide, for weight loss and type 2 diabetes.
The drugmaker said earlier this month it expects to launch the drug in the next four to five years.
BIOCON
Indian drugmaker Biocon BION.NS is developing its own version of Novo's Wegovy, as the drug is set to lose exclusivity next year in emerging markets such as India, Brazil, Mexico, and Saudi Arabia.
ZYDUS LIFESCIENCES
India's Zydus Lifesciences ZYDU.NS is developing the generic version of Semaglutide and plans on launching the drug after its patent expires in India.
CIPLA
Cipla CIPL.NS, India's third-largest drugmaker by sales, is among the Indian drugmakers making cheaper versions of Novo's Wegovy.
Cipla has also said it is open to partnering with Lilly to market Mounjaro in India.
DR. REDDY'S
India's Dr. Reddy's REDY.NS has said it plans to launch generic versions of Semaglutide in all the markets as Novo's patent expires.
LUPIN
India's Lupin LUPN.NS is another generic drugmaker looking to grab a share of the burgeoning obesity treatment market with its own version of Novo's Wegovy.
NATCO, MANKIND PHARMA, AUROBINDO PHARMA
Media reports say India's Natco Pharma NATP.NS, Mankind Pharma MNKI.NS, Aurobindo Pharma ARBN.NS are also developing cheaper versions of Novo's Wegovy.
Reuters was not able to independently verify the reports.
(Reporting by Mariam Sunny and Puyaan Singh in Bengaluru; Editing by Maju Samuel)
(([email protected];))
Updates paragraph 1, adds details on Novo Nordisk and Eli Lilly
June 26 (Reuters) - India's drug regulator on Thursday approved the launch of pre-filled injector pens of Eli Lilly's LLY.N blockbuster weight-loss drug, Mounjaro, giving the company more options to compete with rival Novo Nordisk's NOVOb.CO recently launched Wegovy.
India, the world's most populous country, has high obesity rates and the second-highest number of people with type 2 diabetes. Around 11% of Indian adults are expected to become obese by 2035, according to the World Obesity Federation Atlas.
Here are the local and international drugmakers also eyeing the Indian market and looking to introduce rivals to Lilly's drug:
NOVO NORDISK
The Danish drugmaker launched its blockbuster weight-loss drug Wegovy in India on June 24, three months after Eli Lilly began marketing its rival product Mounjaro.
The active ingredient in Wegovy is semaglutide, which is likely to go off-patent in 2026 in India.
Wegovy and Lilly's Mounjaro belong to the same class of treatments called GLP-1 agonists, which soared into popularity globally triggering a shortage of supply.
GLP-1 drugs mimic a gut hormone that helps control blood sugar levels and slow digestion, making people feel fuller for longer.
ELI LILLY
Lilly started selling Mounjaro in India in late March for diabetes and obesity, beating rival Novo to the market. The doses available were 2.5 mg and 5 mg vials.
On Thursday, Mounjaro KwikPen - for once-weekly use - was approved by the Central Drugs Standard Control Organization for six dose strengths of 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg and 15 mg.
SUN PHARMA
Sun Pharmaceutical SUN.NS, India's largest drugmaker by revenue, is developing its own GLP-1 treatment, utreglutide, for weight loss and type 2 diabetes.
The drugmaker said earlier this month it expects to launch the drug in the next four to five years.
BIOCON
Indian drugmaker Biocon BION.NS is developing its own version of Novo's Wegovy, as the drug is set to lose exclusivity next year in emerging markets such as India, Brazil, Mexico, and Saudi Arabia.
ZYDUS LIFESCIENCES
India's Zydus Lifesciences ZYDU.NS is developing the generic version of Semaglutide and plans on launching the drug after its patent expires in India.
CIPLA
Cipla CIPL.NS, India's third-largest drugmaker by sales, is among the Indian drugmakers making cheaper versions of Novo's Wegovy.
Cipla has also said it is open to partnering with Lilly to market Mounjaro in India.
DR. REDDY'S
India's Dr. Reddy's REDY.NS has said it plans to launch generic versions of Semaglutide in all the markets as Novo's patent expires.
LUPIN
India's Lupin LUPN.NS is another generic drugmaker looking to grab a share of the burgeoning obesity treatment market with its own version of Novo's Wegovy.
NATCO, MANKIND PHARMA, AUROBINDO PHARMA
Media reports say India's Natco Pharma NATP.NS, Mankind Pharma MNKI.NS, Aurobindo Pharma ARBN.NS are also developing cheaper versions of Novo's Wegovy.
Reuters was not able to independently verify the reports.
(Reporting by Mariam Sunny and Puyaan Singh in Bengaluru; Editing by Maju Samuel)
(([email protected];))
May 14 (Reuters) - Mankind Pharma Ltd MNKI.NS:
TAX AUTHORITY RAISES ADDITIONAL TAX DEMAND OF 763 MILLION RUPEES
Source text: ID:nNSE2VC4dZ
Further company coverage: MNKI.NS
(([email protected];;))
May 14 (Reuters) - Mankind Pharma Ltd MNKI.NS:
TAX AUTHORITY RAISES ADDITIONAL TAX DEMAND OF 763 MILLION RUPEES
Source text: ID:nNSE2VC4dZ
Further company coverage: MNKI.NS
(([email protected];;))
April 14 (Reuters) - Mankind Pharma Ltd MNKI.NS:
TO INCORPORATE WHOLLY OWNED SUBSIDIARY IN RUSSIA
TO INCORPORATE WHOLLY OWNED SUBSIDIARY FOR CSR ACTIVITIES
Source text: ID:nBSE5RPMT8
Further company coverage: MNKI.NS
(([email protected];;))
April 14 (Reuters) - Mankind Pharma Ltd MNKI.NS:
TO INCORPORATE WHOLLY OWNED SUBSIDIARY IN RUSSIA
TO INCORPORATE WHOLLY OWNED SUBSIDIARY FOR CSR ACTIVITIES
Source text: ID:nBSE5RPMT8
Further company coverage: MNKI.NS
(([email protected];;))
March 28 (Reuters) - Mankind Pharma Ltd MNKI.NS:
MANKIND PHARMA LTD - NCLT APPROVES AMALGAMATION OF BSV PHARMA WITH BHARAT SERUMS AND VACCINES
Source text: ID:nBSE1dlv3M
Further company coverage: MNKI.NS
(([email protected];))
March 28 (Reuters) - Mankind Pharma Ltd MNKI.NS:
MANKIND PHARMA LTD - NCLT APPROVES AMALGAMATION OF BSV PHARMA WITH BHARAT SERUMS AND VACCINES
Source text: ID:nBSE1dlv3M
Further company coverage: MNKI.NS
(([email protected];))
March 20 (Reuters) - Eli Lilly LLY.N on Thursday launched in India its diabetes and weight-loss drug, Mounjaro, which has already clocked in over $20 billion in global sales since its initial U.S. launch in 2022.
India, the world's most populous country, has high obesity rates and the second-highest number of people with type 2 diabetes. Around 11% of Indian adults are expected to become obese by 2035, according to the World Obesity Federation Atlas.
Here are the local and international drugmakers also eyeing the Indian market and looking to introduce rivals to Lilly's drug:
NOVO NORDISK
The Danish drugmaker NOVOb.CO had said it aims to launch its blockbuster weight-loss drug, Wegovy, in India by 2026.
The active ingredient in Wegovy is semaglutide, which is likely to go off-patent in 2026 in India.
Wegovy and Lilly's Mounjaro belong to the same class of treatments called GLP-1 agonists, which soared into popularity globally triggering a shortage of supply. GLP-1 drugs mimic a gut hormone that helps control blood sugar levels and slow digestion, making people feel fuller for longer.
SUN PHARMA
Sun Pharmaceutical SUN.NS, India's largest drugmaker by revenue, is developing its own GLP-1 treatment, utreglutide, for weight loss and type 2 diabetes.
The drugmaker said earlier this month it expects to launch the drug in the next four to five years.
BIOCON
Indian drugmaker Biocon BION.NS is developing its own version of Novo's Wegovy, as the drug is set to lose exclusivity next year in emerging markets such as India, Brazil, Mexico, and Saudi Arabia.
ZYDUS LIFESCIENCES
India's Zydus Lifesciences ZYDU.NS is developing the generic version of Semaglutide and plans on launching the drug after its patent expires in India.
CIPLA
Cipla CIPL.NS, India's third-largest drugmaker by sales, is among the Indian drugmakers making cheaper versions of Novo's Wegovy.
Cipla has also said it is open to partnering with Lilly to market Mounjaro in India.
DR. REDDY'S
India's Dr. Reddy's REDY.NS has said it plans to launch generic versions of Semaglutide in all the markets as Novo's patent expires.
LUPIN
India's Lupin LUPN.NS is another generic drugmaker looking to grab a share of the burgeoning obesity treatment market with its own version of Novo's Wegovy.
NATCO, MANKIND PHARMA, AUROBINDO PHARMA
Media reports say India's Natco Pharma NATP.NS, Mankind Pharma MNKI.NS, Aurobindo Pharma ARBN.NS are also developing cheaper versions of Novo's Wegovy.
Reuters was not able to independently verify the reports.
(Reporting by Mariam Sunny in Bengaluru; Editing by Maju Samuel)
(([email protected];))
March 20 (Reuters) - Eli Lilly LLY.N on Thursday launched in India its diabetes and weight-loss drug, Mounjaro, which has already clocked in over $20 billion in global sales since its initial U.S. launch in 2022.
India, the world's most populous country, has high obesity rates and the second-highest number of people with type 2 diabetes. Around 11% of Indian adults are expected to become obese by 2035, according to the World Obesity Federation Atlas.
Here are the local and international drugmakers also eyeing the Indian market and looking to introduce rivals to Lilly's drug:
NOVO NORDISK
The Danish drugmaker NOVOb.CO had said it aims to launch its blockbuster weight-loss drug, Wegovy, in India by 2026.
The active ingredient in Wegovy is semaglutide, which is likely to go off-patent in 2026 in India.
Wegovy and Lilly's Mounjaro belong to the same class of treatments called GLP-1 agonists, which soared into popularity globally triggering a shortage of supply. GLP-1 drugs mimic a gut hormone that helps control blood sugar levels and slow digestion, making people feel fuller for longer.
SUN PHARMA
Sun Pharmaceutical SUN.NS, India's largest drugmaker by revenue, is developing its own GLP-1 treatment, utreglutide, for weight loss and type 2 diabetes.
The drugmaker said earlier this month it expects to launch the drug in the next four to five years.
BIOCON
Indian drugmaker Biocon BION.NS is developing its own version of Novo's Wegovy, as the drug is set to lose exclusivity next year in emerging markets such as India, Brazil, Mexico, and Saudi Arabia.
ZYDUS LIFESCIENCES
India's Zydus Lifesciences ZYDU.NS is developing the generic version of Semaglutide and plans on launching the drug after its patent expires in India.
CIPLA
Cipla CIPL.NS, India's third-largest drugmaker by sales, is among the Indian drugmakers making cheaper versions of Novo's Wegovy.
Cipla has also said it is open to partnering with Lilly to market Mounjaro in India.
DR. REDDY'S
India's Dr. Reddy's REDY.NS has said it plans to launch generic versions of Semaglutide in all the markets as Novo's patent expires.
LUPIN
India's Lupin LUPN.NS is another generic drugmaker looking to grab a share of the burgeoning obesity treatment market with its own version of Novo's Wegovy.
NATCO, MANKIND PHARMA, AUROBINDO PHARMA
Media reports say India's Natco Pharma NATP.NS, Mankind Pharma MNKI.NS, Aurobindo Pharma ARBN.NS are also developing cheaper versions of Novo's Wegovy.
Reuters was not able to independently verify the reports.
(Reporting by Mariam Sunny in Bengaluru; Editing by Maju Samuel)
(([email protected];))
** Shares of India's Mankind Pharma MNKI.NS drop as much as 5.3% to 2,168.20 rupees; last down 1.4%
** Stock on track for third straight session of decline
** Drugmaker says it received tax demand worth 1.12 billion rupees ($13 million) from the income tax department
** Trading volume at more than 694,000 shares, same as 30-day moving average
** Average rating of 14 analysts on MNKI at "buy"; median PT is 2,828.50 rupees - data compiled by LSEG
** Stock down 22% YTD vs 15% drop in the pharma index .NIPHARM
($1 = 87.3675 Indian rupees)
(Reporting by Kashish Tandon in Bengaluru)
** Shares of India's Mankind Pharma MNKI.NS drop as much as 5.3% to 2,168.20 rupees; last down 1.4%
** Stock on track for third straight session of decline
** Drugmaker says it received tax demand worth 1.12 billion rupees ($13 million) from the income tax department
** Trading volume at more than 694,000 shares, same as 30-day moving average
** Average rating of 14 analysts on MNKI at "buy"; median PT is 2,828.50 rupees - data compiled by LSEG
** Stock down 22% YTD vs 15% drop in the pharma index .NIPHARM
($1 = 87.3675 Indian rupees)
(Reporting by Kashish Tandon in Bengaluru)
Feb 28 (Reuters) - Mankind Pharma Ltd MNKI.NS:
MANKIND PHARMA LTD - INCOME TAX DEPARTMENT RAISES ADDITIONAL TAX DEMAND OF 1.12 BILLION RUPEES
MANKIND PHARMA LTD - BELIEVES TAX DEMAND IS NOT TENABLE IN LAW
MANKIND PHARMA LTD - DOES NOT EXPECT MATERIAL IMPACT ON FINANCIALS OR OPERATIONS
MANKIND PHARMA LTD - TO PURSUE APPEAL AGAINST INCOME TAX ORDER
Source text: ID:nBSE7Hh9mP
Further company coverage: MNKI.NS
(([email protected];))
Feb 28 (Reuters) - Mankind Pharma Ltd MNKI.NS:
MANKIND PHARMA LTD - INCOME TAX DEPARTMENT RAISES ADDITIONAL TAX DEMAND OF 1.12 BILLION RUPEES
MANKIND PHARMA LTD - BELIEVES TAX DEMAND IS NOT TENABLE IN LAW
MANKIND PHARMA LTD - DOES NOT EXPECT MATERIAL IMPACT ON FINANCIALS OR OPERATIONS
MANKIND PHARMA LTD - TO PURSUE APPEAL AGAINST INCOME TAX ORDER
Source text: ID:nBSE7Hh9mP
Further company coverage: MNKI.NS
(([email protected];))
Feb 27 (Reuters) - Mankind Pharma Ltd MNKI.NS:
MANKIND PHARMA - NCLT APPROVES AMALGAMATION OF SHREE JEE LAB, JPR LABS, JASPACK WITH CO
Source text: ID:nNSE3WY0QT
Further company coverage: MNKI.NS
(([email protected];;))
Feb 27 (Reuters) - Mankind Pharma Ltd MNKI.NS:
MANKIND PHARMA - NCLT APPROVES AMALGAMATION OF SHREE JEE LAB, JPR LABS, JASPACK WITH CO
Source text: ID:nNSE3WY0QT
Further company coverage: MNKI.NS
(([email protected];;))
Jan 24 - ** Shares of India's Mankind Pharma MNKI.NS fall 2.2% to 2,487.15 rupees, their lowest level in nearly three months
** Co reported lower-than-expected Q3 profit on Thursday due to a sharp rise in expenses
** Estimates missed due to higher interest outgo in the quarter, says Motilal Oswal
** Adds, weakness in acute therapy segment led to co's underperformance over Indian pharma market (IPM) sales growth in Dec. quarter
** MNKI says the $1.6-billion acquisition of Bharat Serums and Vaccines also led to rise in costs and hurt quarterly results
** Analysts' average rating on stock at "buy", median PT is 2,852.50 rupees
** Stock down 8.5% so far in January, on track for biggest monthly decline since May 2024
** Pharma index .NIPHARM has lost 6.2% in January so far
(Reporting by Vivek Kumar M)
Jan 24 - ** Shares of India's Mankind Pharma MNKI.NS fall 2.2% to 2,487.15 rupees, their lowest level in nearly three months
** Co reported lower-than-expected Q3 profit on Thursday due to a sharp rise in expenses
** Estimates missed due to higher interest outgo in the quarter, says Motilal Oswal
** Adds, weakness in acute therapy segment led to co's underperformance over Indian pharma market (IPM) sales growth in Dec. quarter
** MNKI says the $1.6-billion acquisition of Bharat Serums and Vaccines also led to rise in costs and hurt quarterly results
** Analysts' average rating on stock at "buy", median PT is 2,852.50 rupees
** Stock down 8.5% so far in January, on track for biggest monthly decline since May 2024
** Pharma index .NIPHARM has lost 6.2% in January so far
(Reporting by Vivek Kumar M)
Jan 23 (Reuters) - Mankind Pharma Ltd MNKI.NS:
Q3 CONSOL NET PROFIT 3.8 BILLION RUPEES; IBES PROFIT EST. 4.48 BILLION RUPEES
Q3 CONSOL REVENUE FROM OPERATIONS 32.3 BILLION RUPEES; IBES EST. 32.28 BILLION RUPEES
Source text: [ID:]
Further company coverage: MNKI.NS
(([email protected];;))
Jan 23 (Reuters) - Mankind Pharma Ltd MNKI.NS:
Q3 CONSOL NET PROFIT 3.8 BILLION RUPEES; IBES PROFIT EST. 4.48 BILLION RUPEES
Q3 CONSOL REVENUE FROM OPERATIONS 32.3 BILLION RUPEES; IBES EST. 32.28 BILLION RUPEES
Source text: [ID:]
Further company coverage: MNKI.NS
(([email protected];;))
** Shares of Mankind Pharma MNKI.NS shed ~4% to 2,601.60 rupees
** Macquarie downgrades stock to "underperform", cuts PT to 2,150 rupees from 2,300 rupees
** Macquarie's PT second-lowest on Street - LSEG
** MNKI's domestic formulations business hurt due to slower growth in acute therapies, which makes up ~60% of MNKI's revenue, Macquarie says
** Adds, while management expects strong growth and improved profitability from Bharat Serums and Vaccines acquisition in near term, brokerage highlights uncertainty over execution
** Brokerage says BSV acquisition would add to revenue growth but would weigh on profit growth
** Significant margin expansion from BSV acquisition is challenging due to lower gross margins and different selling channel for BSV's products - Macquarie
** Analysts' average rating on MNKI at "buy"; median PT is 2,852.50 rupees - LSEG data
(Reporting by Kashish Tandon in Bengaluru)
** Shares of Mankind Pharma MNKI.NS shed ~4% to 2,601.60 rupees
** Macquarie downgrades stock to "underperform", cuts PT to 2,150 rupees from 2,300 rupees
** Macquarie's PT second-lowest on Street - LSEG
** MNKI's domestic formulations business hurt due to slower growth in acute therapies, which makes up ~60% of MNKI's revenue, Macquarie says
** Adds, while management expects strong growth and improved profitability from Bharat Serums and Vaccines acquisition in near term, brokerage highlights uncertainty over execution
** Brokerage says BSV acquisition would add to revenue growth but would weigh on profit growth
** Significant margin expansion from BSV acquisition is challenging due to lower gross margins and different selling channel for BSV's products - Macquarie
** Analysts' average rating on MNKI at "buy"; median PT is 2,852.50 rupees - LSEG data
(Reporting by Kashish Tandon in Bengaluru)
Jan 15 (Reuters) - Mankind Pharma Ltd MNKI.NS:
MANKIND PHARMA - GOT TAX ORDER FOR PENALTY OF 22.8 MILLION RUPEES
Source text: ID:nNSE3NLZ8y
Further company coverage: MNKI.NS
(([email protected];))
Jan 15 (Reuters) - Mankind Pharma Ltd MNKI.NS:
MANKIND PHARMA - GOT TAX ORDER FOR PENALTY OF 22.8 MILLION RUPEES
Source text: ID:nNSE3NLZ8y
Further company coverage: MNKI.NS
(([email protected];))
Jan 7 (Reuters) - Mankind Pharma Ltd MNKI.NS:
REMAINING 56.31% SHARES OF BHARAT SERUMS AND VACCINES PLEDGED IN FAVOUR OF CATALYST TRUSTEESHIP
Source text: ID:nBSE4Hw2Y5
Further company coverage: MNKI.NS
(([email protected];;))
Jan 7 (Reuters) - Mankind Pharma Ltd MNKI.NS:
REMAINING 56.31% SHARES OF BHARAT SERUMS AND VACCINES PLEDGED IN FAVOUR OF CATALYST TRUSTEESHIP
Source text: ID:nBSE4Hw2Y5
Further company coverage: MNKI.NS
(([email protected];;))
Dec 26 (Reuters) - Mankind Pharma Ltd MNKI.NS:
ONYX BIOTEC - COMPLETION OF AUDIT OF DRY POWDER INJECTION BY MANKIND PHARMA
Source text: [ID:]
Further company coverage: MNKI.NS
(([email protected];;))
Dec 26 (Reuters) - Mankind Pharma Ltd MNKI.NS:
ONYX BIOTEC - COMPLETION OF AUDIT OF DRY POWDER INJECTION BY MANKIND PHARMA
Source text: [ID:]
Further company coverage: MNKI.NS
(([email protected];;))
Nov 22 (Reuters) - Mankind Pharma Ltd MNKI.NS:
GETS GST ORDER WITH PENALTY OF 29.1 MILLION RUPEES
Source text: ID:nBSE39nB57
Further company coverage: MNKI.NS
(([email protected];;))
Nov 22 (Reuters) - Mankind Pharma Ltd MNKI.NS:
GETS GST ORDER WITH PENALTY OF 29.1 MILLION RUPEES
Source text: ID:nBSE39nB57
Further company coverage: MNKI.NS
(([email protected];;))
More Mid Cap Ideas
See similar 'Mid' cap companies with recent activity
Promoter Buying
Companies where the promoters are bullish
Capex
Companies investing on expansion
Superstar Investor
Companies where well known investors have invested
Popular questions
- Business
- Financials
- Share Price
- Shareholdings
What does Mankind Pharma do?
Mankind Pharma is India’s one of the leading pharmaceutical company with a diversified portfolio - from pharma and super specialty to consumer healthcare backed by strong in-house R&D capabilities with an established and deeply penetrated presence across India. The company is engaged in developing, manufacturing and marketing a diverse range of pharmaceutical formulations across various acute and chronic therapeutic areas, as well as several consumer healthcare products.
Who are the competitors of Mankind Pharma?
Mankind Pharma major competitors are Zydus Lifesciences, Lupin, Dr. Reddy's Labs., Aurobindo Pharma, Cipla, Alkem Laboratories, Glenmark Pharma.. Market Cap of Mankind Pharma is ₹1,04,535 Crs. While the median market cap of its peers are ₹1,13,215 Crs.
Is Mankind Pharma financially stable compared to its competitors?
Mankind Pharma seems to be financially stable compared to its competitors. The probability of it going bankrupt or facing a financial crunch seem to be lower than its immediate competitors.
Does Mankind Pharma pay decent dividends?
The company seems to be paying a very low dividend. Investors need to see where the company is allocating its profits. Mankind Pharma latest dividend payout ratio is 0% and 3yr average dividend payout ratio is 0%
How has Mankind Pharma allocated its funds?
Companies resources are allocated to majorly productive assets like Plant & Machinery
How strong is Mankind Pharma balance sheet?
Balance sheet of Mankind Pharma is strong. But short term working capital might become an issue for this company.
Is the profitablity of Mankind Pharma improving?
The profit is oscillating. The profit of Mankind Pharma is ₹1,926 Crs for TTM, ₹1,991 Crs for Mar 2025 and ₹1,913 Crs for Mar 2024.
Is the debt of Mankind Pharma increasing or decreasing?
The net debt of Mankind Pharma is decreasing. Latest net debt of Mankind Pharma is ₹5,722 Crs as of Mar-26. This is less than Mar-25 when it was ₹7,192 Crs.
Is Mankind Pharma stock expensive?
Mankind Pharma is expensive when considering the PE ratio, however latest EV/EBIDTA is < 3 yr avg EV/EBIDTA. Latest PE of Mankind Pharma is 54.65, while 3 year average PE is 51.82. Also latest EV/EBITDA of Mankind Pharma is 30.48 while 3yr average is 34.76.
Has the share price of Mankind Pharma grown faster than its competition?
Mankind Pharma has given lower returns compared to its competitors. Mankind Pharma has grown at ~14.2% over the last 3yrs while peers have grown at a median rate of 24.5%
Is the promoter bullish about Mankind Pharma?
Promoters stake in the company seems stable, and we need to go through filings and allocation of resources to gauge promoter bullishness. Latest quarter promoter holding in Mankind Pharma is 72.66% and last quarter promoter holding is 72.66%.
Are mutual funds buying/selling Mankind Pharma?
The mutual fund holding of Mankind Pharma is increasing. The current mutual fund holding in Mankind Pharma is 10.36% while previous quarter holding is 9.3%.